Olema Pharmaceuticals, Inc. insider Cyrus Harmon reported sales of Olema common stock that occurred on July 23, 2026. The Form 4, filed July 27, 2026, describes two sale transactions involving a total of 727,770 shares of OLMA common stock. The first reported sale covered 12,500 shares at a weighted-average price of $11.579 per share, generating approximate gross proceeds of $144,738. The filing states that the shares in that transaction were sold in a price range of $11.52 to $11.675. The second reported sale covered 715,270 shares at a weighted-average price of $11.714 per share, for approximate gross proceeds of $8.38 million. Those shares were sold at prices ranging from $11.70 to $11.775. Together, the reported sales amounted to roughly $8.52 million in gross proceeds before any taxes, commissions, or other costs. The filing’s explanatory notes say the issuer, SEC staff, or any Olema security holder may request full details on the number of shares sold at each individual price within the reported ranges. The filing also notes that the shares are held by Harmon Family Investors LLC, and that Cyrus Harmon is the manager of that entity. As a result, the reported ownership is indirect beneficial ownership through the LLC. The document excerpt does not provide a visible post-transaction ownership total or list a transaction code, but the pricing notes identify the transactions as sales of common stock. The filing was signed on Harmon’s behalf by Shawnte Mitchell, attorney-in-fact, on July 27, 2026.